Zydus Lifesciences has informed that it enclosed a copy of press release dated January 19, 2024 titled ‘Zydus and Synthon enter into an exclusive licensing and supply agreement for Palbociclib Tablets (generic version of IBRANCE®) for the US market.
The above information is a part of company’s filings submitted to BSE.